Efficacy of CeraVe® Moisturizing Cream on Skin Pruritus in Elderly Patients
NCT ID: NCT05779150
Last Updated: 2023-03-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
50 participants
INTERVENTIONAL
2023-02-26
2024-02-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
type of study: clinical trial participant population:in patients with chronic elderly pruritus \[question 1\] Evaluate the CeraVe® moisturizing cream's efficiency on the improvement of skin barrier in patients with chronic elderly pruritus, including improvements of redness, dryness/squamation, itching, burning, tingling, tightness and other factors.
\[question 2\] Evaluate the tolerance of CeraVe® Moisturising Cream. \[question 3\] Evaluate the product experience of patients who were utilizing CeraVe® Moisturising Cream.
This trial utilizing simple randomization, the left and right calves of paticipants were randomly divided into test side(applicating CeraVe® Moisturising Cream ) and control side (applicating Standard Cream)according to random number representation. Grouping results were double-blinded.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Compare the Skin Barrier Repair Function of Two Ceramide Containing Moisturizers
NCT04185025
A Clinical Study to Assess the Safety and Effectiveness of Test Product in Healthy Adult Human Subjects With Dry or Sensitive Skin
NCT06929988
Skin Health and Effectiveness of Standardized Skin Care Regimens in Nursing Home Residents
NCT02216526
Paraffin Bath Therapy for Chronic Hand Eczema
NCT04510961
Xerotic Dermatitis in Aged People
NCT01806935
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Case group
Routine treatment together with once applicating CeraVe® Moisturising Cream after daily bath.
CeraVe® Moisturising Cream
CeraVe® Moisturising Cream contains 3 kinds of skin-native ceramides, which can protect the skin against external stimuli, strengthen the damaged skin barrier, fill the intercellular lipids to deeply trap water, relieve dry skin, and increase skin hydration.
Control Group
Routine treatment together with once applicating Standard Cream after daily bath.
Standard Cream
placebo cream
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CeraVe® Moisturising Cream
CeraVe® Moisturising Cream contains 3 kinds of skin-native ceramides, which can protect the skin against external stimuli, strengthen the damaged skin barrier, fill the intercellular lipids to deeply trap water, relieve dry skin, and increase skin hydration.
Standard Cream
placebo cream
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Clinician evaluates dry pruritus or patient complains of pruritus, which lasts for more than 1 month.
* Patients informed consent to the purpose and content of the research, willing to cooperate with follow-up observation. Have good communication and understanding skills.
* Patients are willing to share photos for medical research purpose.
Exclusion Criteria
* The affected area is complicated by other skin diseases that may affect the efficacy evaluation
* Those who are allergic to the ingredients of this product or with allergic constitution
* Patients who have severe heart, brain, lung, or liver damage.
* Those who have received systemic or local antiallergic drug treatment within 2 weeks before enrollment of this study.
* Those who attending other clinical drug trials within 4 weeks before enrollment of this study.
* Patients with a history of alcohol or drug abuse.
* Patients who are unwilling to sign the informed consent form, and those who are unwilling to cooperate.
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Zhongshan Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yu Hu, Dr
Role: PRINCIPAL_INVESTIGATOR
Shanghai Zhongshan Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zhongshan Hospital,Fudan University
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B2023-004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.